Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.
van der Vaart T,Plasschaert E,Rietman AB,Renard M,Oostenbrink R,Vogels A,de Wit MC,Descheemaeker MJ,Vergouwe Y,Catsman-Berrevoets CE,Legius E,Elgersma Y,Moll HA
The Lancet. Neurology 2013 Nov 1112
Add Experiment
Ctrl + Click on this edge to list all its experiments. If you’ve clicked the “Show all evidence” button, you can Shift + Click on a second edge for the same pair of nodes to compare the experiments with conflicting evidence.
Error! You are not authorized to modify the contents of this paper. Contact us for further information.
[{"result":"No Change","is_hypothetical":"false","stat_test":"linear regression","measure":"grooved pegboard test","condition":"Neurofibromatosis type I","sample_size":43,"age_min":13,"dose_max":40,"dose_min":10,"age_max":16,"OutcomeNotes":"dominant hand","duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"e89ae986-8e8e-41d3-ab27-df1f4dab7651","p_value":0.14,"intervention":"simvastatin","outcome":"fine motor coordination","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","is_hypothetical":"false","stat_test":"linear regression","measure":"grooved pegboard test","condition":"Neurofibromatosis type I","sample_size":43,"age_min":8,"dose_max":20,"dose_min":10,"age_max":12,"OutcomeNotes":"dominant hand","duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"c4b3d9f7-5e29-4de9-9cd8-7e3292c92dc6","p_value":0.14,"intervention":"simvastatin","outcome":"fine motor coordination","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","stat_test":"linear regression","is_hypothetical":"false","measure":"youth self-report (YSR) form","condition":"Neurofibromatosis type I","sample_size":43,"age_min":11,"dose_max":20,"dose_min":10,"age_max":16,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"ec0ccb6f-4d50-4cf2-ad73-bf5af642f5f3","p_value":0.48,"intervention":"simvastatin","outcome":"internalising behavioral problems","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","stat_test":"linear regression","is_hypothetical":"false","measure":"child health questionnaire–parent form 50 (CHQ-PF50)","condition":"Neurofibromatosis type I","sample_size":43,"age_min":13,"dose_max":40,"dose_min":10,"age_max":16,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"0b414393-f3a2-4ed3-b68e-93bd3786afd7","p_value":0.89,"intervention":"simvastatin","outcome":"psychosocial quality of life (CHQ-PF50)","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","stat_test":"linear regression","is_hypothetical":"false","measure":"child health questionnaire–parent form 50 (CHQ-PF50)","condition":"Neurofibromatosis type I","sample_size":43,"age_min":8,"dose_max":20,"dose_min":10,"age_max":12,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"b48bef68-990d-43b9-9b2a-947618fb3e4d","p_value":0.89,"intervention":"simvastatin","outcome":"psychosocial quality of life (CHQ-PF50)","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","is_hypothetical":"false","stat_test":"linear regression","measure":"teacher report form","condition":"Neurofibromatosis type I","sample_size":43,"age_min":13,"dose_max":40,"dose_min":10,"age_max":16,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"1bc93204-f607-4dbe-bd71-acebd1f2b43f","p_value":0.64,"intervention":"simvastatin","outcome":"school performance","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","is_hypothetical":"false","stat_test":"linear regression","measure":"teacher report form","condition":"Neurofibromatosis type I","sample_size":43,"age_min":8,"dose_max":20,"dose_min":10,"age_max":12,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"9d937d30-1c59-4565-8c97-f92be462e8b0","p_value":0.64,"intervention":"simvastatin","outcome":"school performance","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","is_hypothetical":"false","stat_test":"linear regression","measure":"Stroop color word test","condition":"Neurofibromatosis type I","sample_size":43,"age_min":13,"dose_max":40,"dose_min":10,"age_max":16,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"a048b8a0-398f-4f23-b31b-9510db1ee66f","p_value":0.14,"intervention":"simvastatin","outcome":"attention","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","is_hypothetical":"false","stat_test":"linear regression","measure":"Stroop color word test","condition":"Neurofibromatosis type I","sample_size":43,"age_min":8,"dose_max":20,"dose_min":10,"age_max":12,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"ecd0d069-771c-40f0-9b66-0a00613bb036","p_value":0.14,"intervention":"simvastatin","outcome":"attention","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","is_hypothetical":"false","stat_test":"linear regression","measure":"Rey complex figure test (CFT)","condition":"Neurofibromatosis type I","sample_size":43,"age_min":13,"dose_max":40,"dose_min":10,"age_max":16,"OutcomeNotes":"Rey complex figure test–delayed recall","duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"84c4410e-ae67-41e2-b995-87a5ddfee2a0","p_value":0.34,"intervention":"simvastatin","outcome":"visual-spatial memory","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","is_hypothetical":"false","stat_test":"linear regression","measure":"Rey complex figure test (CFT)","condition":"Neurofibromatosis type I","sample_size":43,"age_min":8,"dose_max":20,"dose_min":10,"age_max":12,"OutcomeNotes":"Rey complex figure test–delayed recall","duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Secondary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"a587a17a-cb18-435b-87e7-453aea7a538c","p_value":0.34,"intervention":"simvastatin","outcome":"visual-spatial memory","type":"undefined"},{"result":"No Change","stat_test":"linear regression","is_hypothetical":"false","measure":"child behaviour checklist (CBCL)","condition":"Neurofibromatosis type I","sample_size":43,"age_min":13,"dose_max":40,"dose_min":10,"age_max":16,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"0c5fa80e-88f6-4906-9a1b-ef11073552ab","p_value":0.96,"intervention":"simvastatin","outcome":"internalising behavioural problems","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","stat_test":"linear regression","is_hypothetical":"false","measure":"child behaviour checklist (CBCL)","condition":"Neurofibromatosis type I","sample_size":43,"age_min":8,"dose_max":20,"dose_min":10,"age_max":12,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"fa16ee15-9044-4cb8-a0d0-e3fae7675e90","p_value":0.96,"intervention":"simvastatin","outcome":"internalising behavioural problems","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","stat_test":"linear regression","is_hypothetical":"false","measure":"child behaviour checklist (CBCL)","condition":"Neurofibromatosis type I","sample_size":43,"age_min":13,"dose_max":40,"dose_min":10,"age_max":16,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"5c33a8d4-6102-47ef-91d3-2851516304db","p_value":0.23,"intervention":"simvastatin","outcome":"attention problems","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","stat_test":"linear regression","is_hypothetical":"false","measure":"child behaviour checklist (CBCL)","condition":"Neurofibromatosis type I","sample_size":43,"age_min":8,"dose_max":20,"dose_min":10,"age_max":12,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"7f12dcdb-763e-40ad-afac-42d07789b783","p_value":0.23,"intervention":"simvastatin","outcome":"attention problems","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","stat_test":"linear regression","is_hypothetical":"false","measure":"Wechsler Intelligence Scale for Children–Revised","condition":"Neurofibromatosis type I","sample_size":43,"age_min":13,"dose_max":40,"dose_min":10,"age_max":16,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"cbf81340-e0d3-4209-b873-42a66395670b","p_value":0.33,"intervention":"simvastatin","outcome":"full-scale intelligence","type":"HAS_NO_CONNECTION_WITH"},{"result":"No Change","stat_test":"linear regression","is_hypothetical":"false","measure":"Wechsler Intelligence Scale for Children–Revised","condition":"Neurofibromatosis type I","sample_size":43,"age_min":8,"dose_max":20,"dose_min":10,"age_max":12,"duration":"365","paper_uuid":"610a294b-d182-4689-aee1-44a9293ae9ce","priority":"Primary","experiment":"Positive","InterventionNotes":"dose-escalating approach","uuid":"ebe10ac2-32ba-49ef-a451-383518dd46d1","p_value":0.33,"intervention":"simvastatin","outcome":"full-scale intelligence","type":"HAS_NO_CONNECTION_WITH"}]
ID
Actions
What Agent
Where Agent
When Agent
Experiment
Agent Approach
What Target
Where Target
When Target
Result
Target Approach
Connection Type
What Second Agent
Where Second Agent
When Second Agent
Second Agent Manipulation
Second Agent Approach
Error! Some values are missing. Enter all values before submitting the form.
